---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000050"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:31:30.951152+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility

## Summary
- Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.
- Pegus brings 25+ years of clinical and business leadership; most recently partner at Morgan Health, formerly EVP at Walmart and CMO at Walgreens.
- Company amended its $2.75B revolving credit agreement, extending maturity to May 2029 for consenting lenders and adjusting the pricing grid.
- Reset EBITDA exclusion cap for restructuring charges to $500M since March 31, 2024 (previously December 31, 2022).

## SEC filing metadata
- accession: 0000885725-24-000050
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/bsx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000050
- JSON: https://secwatch.observer/filing/0000885725-24-000050.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000050.txt

## Key facts
- Executive change
  Cheryl Pegus was appointed as Director at BOSTON SCIENTIFIC CORP.
  - Action: appointed
  - Role: Director
  source text: appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.